(Q30448951)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19707193%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

review article

1 reference

title

Neurological adverse effects caused by cytotoxic and targeted therapies (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19707193%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

0 references

David Schiff

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19707193%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

language of work or name

English

0 references

publication date

25 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19707193%20AND%20SRC:MED&resulttype=core&format=json

Nature Reviews Clinical Oncology

6 February 2020

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19707193%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

volume

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19707193%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

issue

10

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19707193%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

page(s)

596-603

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19707193%20AND%20SRC:MED&resulttype=core&format=json

Oxaliplatin-associated neuropathy: a review

6 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Immediate post-radiotherapy changes in malignant glioma can mimic tumor progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Thalidomide-induced neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Thalidomide neurotoxicity: prospective study in patients with lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Phase I study of the novel epothilone analog ixabepilone (BMS-247550) in patients with advanced solid tumors and lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Changes in neurologic function tests may predict neurotoxicity caused by ixabepilone.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Multi-institutional randomized phase II trial of the epothilone B analog ixabepilone (BMS-247550) with or without estramustine phosphate in patients with progressive castrate metastatic prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Acute transient encephalopathy following paclitaxel treatment in an adolescent with a recurrent suprasellar germinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Acute transient encephalopathy after paclitaxel infusion: report of three cases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Multicenter phase II trial of ABI-007, an albumin-bound paclitaxel, in women with metastatic breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Phase III Trial of Nanoparticle Albumin-Bound Paclitaxel Compared With Polyethylated Castor Oil–Based Paclitaxel in Women With Breast Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Systemic therapy for metastatic colorectal cancer: current options, current evidence

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Integrating oxaliplatin into the management of colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Oxaliplatin-induced neurotoxicity: acute hyperexcitability and chronic neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Oxaliplatin-safety profile: neurotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Acute oxaliplatin-induced peripheral nerve hyperexcitability

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Oxaliplatin-induced neurotoxicity and the development of neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Lhermitte sign and urinary retention: atypical presentation of oxaliplatin neurotoxicity in four patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Carbamazepine for prevention of oxaliplatin-related neurotoxicity in patients with advanced colorectal cancer: final results of a randomised, controlled, multicenter phase II study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advanced colorectal cancer: a randomized, double-blind, placebo-controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

A possible explanation for a neurotoxic effect of the anticancer agent oxaliplatin on neuronal voltage-gated sodium channels

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-Fluorouracil and leucovorin for advanced colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Use of calcium and magnesium salts to reduce oxaliplatin-related neurotoxicity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Plasma and cerebrospinal fluid pharmacokinetics of intravenous temozolomide in non-human primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

MGMT promoter methylation status can predict the incidence and outcome of pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Incidence of early pseudo-progression in a cohort of malignant glioma patients treated with chemoirradiation with temozolomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Canadian recommendations for the treatment of glioblastoma multiforme.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Phase II study of nelarabine (compound 506U78) in children and young adults with refractory T-cell malignancies: a report from the Children's Oncology Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

FDA drug approval summary: nelarabine (Arranon) for the treatment of T-cell lymphoblastic leukemia/lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Plasma and cerebrospinal fluid pharmacokinetics of nelarabine in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Plasma and cerebrospinal fluid pharmacokinetics of clofarabine in nonhuman primates

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

A randomized study of clofarabine versus clofarabine plus low-dose cytarabine as front-line therapy for patients aged 60 years and older with acute myeloid leukemia and high-risk myelodysplastic syndrome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Clofarabine: past, present, and future

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Neurologic complications associated with intrathecal liposomal cytarabine given prophylactically in combination with high-dose methotrexate and cytarabine to patients with acute lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

The proteasome: a suitable antineoplastic target

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Frequency, characteristics, and reversibility of peripheral neuropathy during treatment of advanced multiple myeloma with bortezomib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Bortezomib or high-dose dexamethasone for relapsed multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Bortezomib-induced peripheral neurotoxicity: a neurophysiological and pathological study in the rat.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Bevacizumab plus irinotecan in recurrent glioblastoma multiforme

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Reversible posterior leukoencephalopathy syndrome and bevacizumab.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Reversible posterior leukoencephalopathy syndrome after bevacizumab/FOLFIRI regimen for metastatic colon cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Reversible posterior leukoencephalopathy syndrome caused by bevacizumab: report of a case

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Reversible posterior leukoencephalopathy syndrome induced by RAF kinase inhibitor BAY 43-9006

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Sunitinib induced hypertension, thrombotic microangiopathy and reversible posterior leukencephalopathy syndrome.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Reversible posterior leukoencephalopathy syndrome induced by sunitinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Cyclosporine neurotoxicity: a review

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Bevacizumab, bleeding, thrombosis, and warfarin

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

What is the risk of intracranial bleeding during anti-VEGF therapy?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

High frequency of intracerebral hemorrhage in metastatic renal carcinoma patients with brain metastases treated with tyrosine kinase inhibitors targeting the vascular endothelial growth factor receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Safety of anticoagulation use and bevacizumab in patients with glioma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Practical management of patients with chronic myeloid leukemia receiving imatinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Imatinib as a possible cause of severe rhabdomyolysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Subdural hematomas during CML therapy with imatinib mesylate.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Phase I trial of imatinib in children with newly diagnosed brainstem and recurrent malignant gliomas: a Pediatric Brain Tumor Consortium report

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

A systematic review of phase-II trials of thalidomide monotherapy in patients with relapsed or refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Neuropathy in multiple myeloma treated with thalidomide: a prospective study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Neurological toxicity of long-term (>1 yr) thalidomide therapy in patients with multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Incidence and risk factors for thalidomide neuropathy: a prospective study of 135 dermatologic patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Common and rare side-effects of low-dose thalidomide in multiple myeloma: focus on the dose-minimizing peripheral neuropathy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Toxicity profile of the immunomodulatory thalidomide analogue, lenalidomide: phase I clinical trial of three dosing schedules in patients with solid malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

A phase I trial of lenalidomide in patients with recurrent primary central nervous system tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Treatment of plasma cell dyscrasias with lenalidomide

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

VTD combination therapy with bortezomib-thalidomide-dexamethasone is highly effective in advanced and refractory multiple myeloma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

The addition of liposomal doxorubicin to bortezomib, thalidomide and dexamethasone significantly improves clinical outcome of advanced multiple myeloma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2009.128

Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel

31 March 2020

1 reference

12 December 2020

Acute encephalopathy: a new toxicity associated with high-dose paclitaxel

1 reference

12 December 2020

Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma

1 reference

12 December 2020

Management of thalidomide toxicity

1 reference

12 December 2020

10.1038/NRCLINONC.2009.128

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19707193%20AND%20SRC:MED&resulttype=core&format=json

6 February 2020

1 reference